CSIMarket


Haemonetics Corporation  (HAE)
Other Ticker:  
 

Haemonetics Corporation

HAE's Fundamental analysis








Looking into Haemonetics growth rates, revenue grew by 12.66 % in IV. Quarter 2024 from the same quarter a year ago.

Medical Equipment & Supplies industry recorded growth of revenues by 7.26 %

Haemonetics's net profit deacreased by -30.68 % in IV. Quarter 2024 year on year, to $20 millions.

More on HAE's Growth


Haemonetics
current PE on trailing twelve month basis is above Medical Equipment & Supplies industry average.

Haemonetics PEG ratio is at 18.87 Haemonetics realized cash outflow of $ -2.06per share in trailing twelve-month period.
Company
41.7
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.74.
Medical Equipment & Supplies industry's Price to Sales ratio is at 4.07.


More on HAE's Valuation
 
 Total Debt (Millions $) 808
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 392,368
 Net Income/Employee (TTM) $ 35,250
 Receivable Turnover (TTM) 6.8
 Tangible Book Value (Per Share $) -0.22

Haemonetics
current PE on trailing twelve month basis is above Medical Equipment & Supplies industry average.

Haemonetics PEG ratio is at 18.87 Haemonetics realized cash outflow of $ -2.06per share in trailing twelve-month period.
Company
41.7
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 3.74.
Medical Equipment & Supplies industry's Price to Sales ratio is at 4.07.

Haemonetics Price to Book Ratio is at 5.09 higher than Indusry Avg. of -627.59, and higher than S&P 500 Avg. of 0.01

More on HAE's Valuation

  Market Capitalization (Millions $) 4,891
  Shares Outstanding (Millions) 51
  Employees 3,335
  Revenues (TTM) (Millions $) 1,309
  Net Income (TTM) (Millions $) 118
  Cash Flow (TTM) (Millions $) -106
  Capital Exp. (TTM) (Millions $) -66
  Total Debt (Millions $) 808
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 392,368
  Net Income/Employee(TTM) $ 35,250
  Receivable Turnover Ratio (TTM) 6.8
  Tangible Book Value (Per Share $) -0.22

  Market Capitalization (Millions $) 4,891
  Shares Outstanding (Millions) 51
  Employees 3,335
  Revenues (TTM) (Millions $) 1,309
  Net Income (TTM) (Millions $) 118
  Cash Flow (TTM) (Millions $) -106
  Capital Exp. (TTM) (Millions $) -66


    HAE's Profitability Comparisons
Haemonetics faced margin deterioraten, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 8.71 % from 13.69 % in III. Quarter.

Haemonetics net profit margin of 5.92 % is currently ranking no. 33 in Medical Equipment & Supplies industry, ranking no. 93 in Healthcare sector and number 1272 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 2.56
  Total Debt to Equity (MRQ) 0.84
  Tangible Leverage Ratio (MRQ) -
  Asset Turnover Ratio (TTM) 0.63
  Inventory Turnover Ratio (TTM) 2.06



Haemonetics faced margin deterioraten, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 8.71 % from 13.69 % in III. Quarter.

Haemonetics net profit margin of 5.92 % is currently ranking no. 33 in Medical Equipment & Supplies industry, ranking no. 93 in Healthcare sector and number 1272 in S&P 500.

More on HAE's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com